{Reference Type}: Journal Article
{Title}: Update on iron supplementation in patients with cancer-related anemia.
{Author}: Rodgers GM;
{Journal}: Expert Rev Hematol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 2
{Factor}: 2.819
{DOI}: 10.1080/17474086.2024.2375265
{Abstract}: <B>UNASSIGNED: </B>Numerous clinical trials affirm the efficacy and safety of IV iron to treat cancer-related anemia (CRA). Nonetheless, evaluation and treatment of CRA remains suboptimal.<BR><B>UNASSIGNED: </B>This review summarizes CRA therapy with a focus on iron deficiency and its treatment. The literature search was conducted using the National Library of Medicine (PubMed) database from 2004 to 2024. Topics reviewed include CRA pathophysiology, laboratory diagnosis of iron deficiency, a summary of clinical trial results using IV iron to treat CRA, and safety aspects.<BR><B>UNASSIGNED: </B>Despite overwhelming positive efficacy and safety data, IV iron remains underutilized to treat CRA. This is likely due to persistent (unfounded) concerns about IV iron safety and lack of physician awareness of newer clinical trial data. This leads to poor patient quality of life and patient exposure to anemia treatments that have greater safety risks than IV iron. Solutions to this problem include increased educational efforts and considering alternative treatment models in which other providers separately manage CRA. The recent availability of new oral iron therapy products that are effective in treating anemia of inflammation has the potential to dramatically simplify the treatment of CRA.